Dyne Therapeutics Net Profit Margin Over Time
| DYN Stock | USD 25.73 0.12 0.47% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Dyne Therapeutics Performance and Dyne Therapeutics Correlation. Dyne |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.58) | Return On Assets (0.40) | Return On Equity (0.69) |
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Profit Margin Analysis
Compare Dyne Therapeutics and related stocks such as Stoke Therapeutics, Pliant Therapeutics, and Cytokinetics Net Profit Margin Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STOK | (7.5058) | (7.5058) | (7.5058) | (7.5058) | (7.5058) | (7.5058) | (7.5058) | (7.5058) | (7.5058) | (7.5058) | (7.5058) | (7.5058) | (7.5058) | (11.9247) | (12.52) |
| PLRX | 0.0032 | 0.0032 | 0.0032 | 0.0032 | 0.0032 | 0.0032 | 0.0032 | 0.0032 | 0.0032 | 0.0032 | (0.9505) | (2.3649) | (12.545) | (102) | (97.01) |
| CYTK | (1.875) | (11.965) | (5.1614) | (1.1001) | (0.312) | (1.3086) | 0.1546 | (9.5594) | (3.3741) | (5.5476) | (2.94) | (3.4414) | (4.2558) | (69.8863) | (66.39) |
| RVMD | (2.0724) | (2.0724) | (2.0724) | (2.0724) | (2.0724) | (2.0724) | (2.0724) | (2.0724) | (2.0724) | (0.9525) | (2.5163) | (6.1167) | (7.0295) | (37.6828) | (35.8) |
| EWTX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| CGEM | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.09) | (3.24) |
| MLYS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| GLUE | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| DSGN | (2.5 K) | (2.5 K) | (2.5 K) | (2.5 K) | (2.5 K) | (2.5 K) | (2.5 K) | (2.5 K) | (2.5 K) | (2.5 K) | (36.6 K) | (36.6 K) | (36.6 K) | (42.1 K) | (44.2 K) |
| ERAS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Dyne Therapeutics and related stocks such as Stoke Therapeutics, Pliant Therapeutics, and Cytokinetics Net Profit Margin description
The percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue.My Equities
My Current Equities and Potential Positions
| Dyne Therapeutics | DYN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 25.73
Check out Dyne Therapeutics Performance and Dyne Therapeutics Correlation. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Dyne Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.